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Accumulation of misfolded alpha-synuclein (a-syn)
into Lewy bodies (LBs) and Lewy neurites (LNs) is a
major hallmark of Parkinson’s disease (PD) and de-
mentia with LBs (DLB). Recent studies showed that
synthetic preformed fibrils (pffs) recruit endogenous
a-syn and induce LB/LNpathology in vitro and in vivo,
thereby implicatingpropagationandcell-to-cell trans-
mission of pathological a-syn as mechanisms for the
progressive spread of LBs/LNs. Here, we demon-
strate that a-syn monoclonal antibodies (mAbs)
reducea-synpff-inducedLB/LNformationandrescue
synapse/neuron loss in primary neuronal cultures by
preventing both pff uptake and subsequent cell-to-
cell transmission of pathology. Moreover, intraperito-
neal (i.p.) administration ofmAbspecific formisfolded
a-syn into nontransgenic mice injected intrastriatally
witha-synpffs reduces LB/LNpathology, ameliorates
substantia nigra dopaminergic neuron loss, and im-
proves motor impairments. We conclude that a-syn
antibodies could exert therapeutic effects in PD/DLB
by blocking entry of pathological a-syn and/or its
propagation in neurons.
INTRODUCTION
Misfolded and aggregated disease-specific proteins such as
a-syn in Parkinson’s disease (PD) and Ab and tau in Alz-
heimer’s disease (AD) are common features of many neurode-
generative diseases (NDs). Self-amplification, propagation, and
transmission of these misfolded proteins are hypothesized as
major contributing factors to disease onset and progression.
The stereotypical and topographical pattern of progressive
spread of protein aggregates in the CNS of AD and PD patients
supports this hypothesis (Braak and Braak, 1991; Braak et al.,
2003). Moreover, the formation of a-syn-positive Lewy bodies
(LBs) in fetal mesencephalic grafts in the striatum of PD pa-
tients is consistent with host-to-graft transfer of pathologic2054 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authorsa-syn (Kordower et al., 2008; Li et al., 2008). Finally, several
in vitro and in vivo studies have demonstrated entry, recruit-
ment, and spread of misfolded a-syn and tau seeds to neigh-
boring cells and/or anatomically connected brain regions
(Costanzo and Zurzolo, 2013; Guo and Lee, 2014). Given
that the cell-to-cell spread of misfolded disease protein likely
involves their release followed by internalization, immuno-
therapy may provide a viable therapeutic approach to treat
these NDs by neutralizing them in the extracellular space
(Prusiner, 2012; Walker and Jucker, 2013).
Efficacy of passive immunotherapy has been demonstrated in
preclinical animal models of NDs. For example, multiple Ab anti-
bodies were shown to reduce Ab burden in preclinical models
and several of them have progressed to clinical trials for treating
AD patients (Lemere and Masliah, 2010). Immunotherapies
against intracellular proteins such as tau (Boutajangout et al.,
2011; d’Abramo et al., 2013; Yanamandra et al., 2013), SOD1
(Gros-Louis et al., 2010), Huntingtin (Wolfgang et al., 2005),
and a-syn (Bae et al., 2012; Masliah et al., 2005, 2011) also
have been explored in transgenic (Tg) mouse models and shown
to decrease protein aggregation and neurodegeneration. How-
ever, only one study demonstrated amechanism of action where
antibody treatment reduced ‘‘seeding’’ activity of tau fibrils
(Yanamandra et al., 2013). Thus, how passive immunotherapy
halts cell-to-cell transmission of a-syn pathology, a process
that is likely central to progression of disease and a prime thera-
peutic target, warrants further investigation.
Recently, we demonstrated that synthetic a-syn preformed
fibrils (pffs) readily enter non-Tg neurons and recruit endogenous
mouse a-syn to form LB/Lewy neurite (LN)-like pathology (Volpi-
celli-Daley et al., 2011). Moreover, a-syn pffs initiated temporal
and spatial spread of a-syn pathology when injected into non-
Tg mice, leading to motoric deficits and loss of dopaminergic
neurons in the substantia nigra pars compacta (SNpc) (Luk
et al., 2012a). Here, we show that a-syn monoclonal antibodies
(mAbs) (Syn211 and Syn303) blocked a-syn pff entry and cell-
to-cell transfer of a-syn pathology in primary neurons, thereby
abrogating templated propagation and transmission of a-syn
pathology to other neurons. Finally, systemic administration of
Syn303 into pff-inoculated wild-type (WT) mice reduced patho-
logic a-syn spread, dopaminergic cell loss, and associated
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Figure 1. a-syn mAbs Reduced a-syn pff-
Induced Insoluble Pathologic Aggregates
(A) Primary WT neurons treated with PBS or hWT
a-syn pffs in the absence (no Ab) or presence of
nonspecific mouse IgG (IgG) or Syn211 and
Syn303 were fixed at 7 days posttreatment in 4%
PFA with or without 1% TX-100 to extract soluble
proteins. Neurons were stained with mAb Syn202
for endogenous mouse a-syn (total a-syn) and
mAb 81A for p-a-syn. In PBS-treated neurons,
a-syn localized to presynaptic compartments
(white arrowheads in top panels) and was TX-100
soluble. In pff-treated neurons (no Ab), a-syn was
recruited from synapses into LB/LN-like pathology
that was hyperphosphorylated and TX-100 insol-
uble. Syn211 and Syn303, but not IgG, reduced
insoluble pathologic aggregates and partially
restored a-syn presynaptic localization. The scale
bars represent 10 mm (top panels with highest
magnification) and 100 mm (all other panels).
(B) Western blot (WB) of mouse a-syn and p-a-syn
levels in neuron lysates sequentially extracted in
1% TX-100 (TX-soluble) followed by 2% SDS (TX-
insoluble) at 14 days after antibody/pff treatments.
TUJ1 served as loading control. High-molecular-
weight a-syn species (**) were detected in TX-
insoluble fractions of pff-treated neurons. a-Syn
pffs recruited endogenous mouse a-syn into TX-
insoluble and hyperphosphorylated aggregates
that were ameliorated by Syn211 and Syn303.
(C) Significant reduction of TX-insoluble p-a-syn
pathology and decreased recruitment of endoge-
nous mouse a-syn into aggregates in cultures
treatedwith pffs and Syn211 or Syn303. There was
no significant difference between no Ab and IgG-
treated cultures, so they were grouped together.
n = 3–6 independent experiments, each performed
in duplicate. Values are mean ± SEM. One-way
ANOVA with Bonferroni’s correction. ***p < 0.001.motor dysfunction caused by a-syn pathology. Together, these
data support the therapeutic potential of a-syn immunotherapy
for treatment of PD.
RESULTS
a-syn mAbs Reduced a-syn pff-Induced Insoluble
Pathologic Aggregates
We have previously reported that synthetic a-syn pffs can seed
and form LB/LN-like pathology in primary neurons (Volpicelli-Da-
ley et al., 2011). To test whether a-syn antibodies can reduce
LB/LNpathology, we treated hippocampal neuronswith different
a-syn mAbs 30 min before transduction with human WT (hWT)
a-syn pffs and evaluated a-syn pathology 7 days posttreatment.
In PBS-treated neurons, endogenous mouse a-syn proteins
were localized to presynaptic compartments, as evidenced by
punctate staining at axon terminals with mAb Syn202 for
total a-syn (Figure 1A). However, this presynaptic pattern wasCell Reports 7, 2054–206clearly perturbed in hWT a-syn pff-treated
neurons due to the recruitment of endog-
enous mouse a-syn into LB/LN-likeinclusions. To determine whether these a-syn aggregates were
insoluble, we extracted neurons using fixation buffer containing
1% Triton X-100 (TX-100). Under this condition, mouse a-syn
within neuronal processes in PBS-treated neurons was
completely extracted,whereas neurons treatedwith pffs showed
TX-100-insoluble aggregates. Addition of Syn211 (specific for
human a-syn; Giasson et al., 2000a) or Syn303 (which binds a
pathological conformation of human and mouse a-syn; Duda
et al., 2002) reduced the extent of fibrillar aggregates andpartially
restored the presynaptic localization of a-syn (Figure 1A, upper
panels). In contrast, control immunoglobulin G (IgG) had no effect
on a-syn aggregation.
Furthermore, the presence of pathological a-syn aggregates
was confirmed using 81A, a mAb specific for a-syn phosphory-
lated at Ser129 (p-a-syn), because previously we established
p-a-syn as a marker of intracellular a-syn pathology as exoge-
nously added hWT a-syn pffs lacked this modification (Volpi-
celli-Daley et al., 2011; Waxman and Giasson, 2008). Notably,5, June 26, 2014 ª2014 The Authors 2055
AD E
B C
Figure 2. a-syn mAbs Reduced a-syn pff-Induced Synaptic Loss and Neuron Death
(A–C) a-syn pffs caused reduction in levels of SNAP25 and Synapsin II compared to PBS at 14 days posttreatment. b-actin served as loading control. Syn211
and Syn303 restored pff-induced synaptic protein loss. n = 4 independent experiments. Values are mean ± SEM. One-way ANOVA with Dunnett’s correction.
*p < 0.05.
(D and E) LDH assay using culture media (D) and neuron counts (NeuN-positive cells; E) from neurons treated with PBS or hWT a-syn pffs in the absence or
presence of Syn211 and Syn303 at 14 days. Syn211 and Syn303 reduced toxicity and neuron death in pff-treated cultures. n = 4 independent experiments. Values
are mean ± SEM. One-way ANOVA with Dunnett’s correction. *p ;< 0.05, **p < 0.01, ***p < 0.001. The scale bar represents 100 mm.81AmAbdetectednumerousTX-100-insoluble, p-a-syn-positive
neuritic and perikaryal inclusions in pff-, but not in PBS-treated
neurons. Significantly, this pathology was dramatically reduced
by Syn211 and Syn303 mAb treatment (Figure 1A, lower panels).
Immunoblot analyses on soluble and insoluble a-syn fractions
after sequentially extracting neurons in 1% TX-100 followed by
2% SDS further support that a-syn mAb treatment reduced
LB/LN-like a-syn pathology. Unlike PBS-treated neurons, those
treated with pffs showed a shift in solubility of endogenous
mouse a-syn with a decrease in the TX-soluble fraction and a
concomitant increase in the TX-insoluble but SDS-extractable
fraction (Figure 1B). The accumulation of p-a-syn in the TX-insol-
uble fraction was also evident. Moreover, both mAbs to a-syn
and p-a-syn detected higher-molecular-weight species of
a-syn in the TX-insoluble fractions of pff-treated cultures
(see ** in Figure 1B) and likely correspond to multimeric, ubiqui-
tinated, and/or other posttranslational modified forms of a-syn
(Jiang et al., 2013; Luk et al., 2009; Sampathu et al., 2003).
Importantly, Syn211 or Syn303 reduced recruitment of endoge-
nous a-syn into LB/LN-like aggregates as indicated by a
76.2% ± 5.9% and 55.4% ± 10.3% reduction in TX-insoluble
a-syn, respectively (Figure 1C, top panel). The accumulation of
TX-insoluble p-a-syn was also reduced by a similar degree
(78.9% ± 5.7% and 49.7% ± 6.2%, respectively; Figure 1C, bot-
tom panel). Moreover, Syn211 and Syn303 reduced a-syn pa-
thology even in cultures where a-syn pffs were present at a 3:1
molar excess to mAbs (Figure S1). Thus, a-syn antibodies are2056 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authorspotent in reducing pff-mediated recruitment of endogenous
mouse a-syn into insoluble, hyperphosphorylated aggregates.
a-syn mAbs Reduced a-syn pff-Induced Synaptic Loss
and Neuron Death
a-syn pathology induced by a-syn pffs not only depleted endog-
enous a-syn from presynaptic terminals but also resulted in
concomitant loss of selective synaptic proteins including
SNAP25 and Synapsin II (Volpicelli-Daley et al., 2011). Signifi-
cantly, Syn211 or Syn303 reduced insoluble a-syn aggregates
and partially restored the presynaptic localization of a-syn (see
arrowheads in Figure 1A). Moreover, treatment with these
mAbs also protected synaptic protein loss induced by a-syn
pffs as indicated by the preservation of SNAP25 and Synapsin
II at levels comparable to PBS-treated neurons (Figures 2A–
2C). Further, pff addition to neurons markedly increased lactate
dehydrogenase (LDH) release and neuron death as demon-
strated by a 40% reduction in the number of surviving neurons
14 days posttreatment. This pff-induced toxicity was reduced by
treatment with Syn211 or Syn303 (Figures 2D and 2E).
a-syn mAbs Prevented pff Entry into Neurons
Because mAbs were added to neurons prior to introduction of
hWT a-syn pffs and that Syn211 exclusively recognizes human
a-syn, we hypothesized that these mAbs reduce pathology by
binding directly to exogenously added hWT a-syn pffs and
blocking their entry into neurons. To test this possibility, we
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Figure 3. a-syn mAbs Remained Outside Neurons and Prevented a-syn pffs Entry into Neurons
(A–C) Time course study characterizing the fate of internalized pffs. Neuronswere treatedwith IgG, Syn211, and Syn303 30min before addition of hWT a-syn pffs.
Neurons were fixed at 6, 12, and 24 hr after antibody/pff treatment and double labeled with Syn204 (detect hWT a-syn pffs) and LAMP1, a lysosomal marker.
(A and B) Representative confocal images indicated intracellular pffs inside a neuron treated with IgG, but not with Syn211 or Syn303 at 6 hr. (C) Quantification of
percentage of cells with intracellular pffs at 6, 12, and 24 hr posttreatment. At all time points examined, Syn211 and Syn303 prevented pffs entry into neurons, as
evidenced by the reduced percentage of neurons with intracellular pffs. Furthermore, neither Syn211 nor Syn303 affected rate of pff turnover. n = 4 independent
experiments. Values are mean ± SEM. One-way ANOVA with Bonferroni’s correction. **p < 0.01, ***p < 0.001.
(D and E) Double labeling of intracellular marker tau, K9JA (rabbit polyclonal antibody [pAb]) with secondary anti-mouse IgG to detect Syn211 or Syn303 (D) or
with Syn204 (E). Lack of colocalization between K9JA and anti-igG secondary and K9JA and Syn204 suggested exogenously added a-syn mAbs and a-syn pffs
were outside of neurons. DAPI served as nuclei marker. The scale bar represents 10 mm.
(F) Double labeling of Syn204 (IgG2a isotype) with anti-IgG1 secondary antibody to detect Syn211 and Syn303. Colocalization between Syn204 and anti-IgG1
secondary antibody suggested majority of pffs and a-syn mAbs remained outside of neurons.
(G) Double labeling of p-a-syn (81A; IgG2a isotype) with anti-IgG1 secondary antibody for Syn211 and Syn303. Lack of colocalization between 81A and anti-IgG1
secondary antibody suggested added Syn211 and Syn303 remained outside of neurons.followed the distribution and fate of both exogenously added
hWT a-syn pffs and mAbs using several experimental
paradigms.
We first monitored the spatial distribution of hWT a-syn pffs in
neurons treated with control IgG, Syn211, or Syn303 for 30 min
followed by addition of hWT a-syn pffs and incubation for 6,
12, and 24 hr. Neurons were fixed and double labeled with
Syn204 (a mAb specific to human a-syn) to detect hWT a-syn
pffs and anti-LAMP1, an intracellular marker for lysosomes.
Internalized pffs were defined as Syn204-positive puncta thatCwere observed juxtaposed to LAMP1 under confocal micro-
scopy. Within 6 hr following pff treatment, internalized pffs
were readily detectable in the perikarya of neurons pretreated
with control IgG (Figure 3A). Quantification showed internalized
hWT a-syn pffs were present in approximately 82.2% ± 4.0%
and 79.5% ± 5.4%of IgG-treated neurons at 6 and 12 hr, respec-
tively. By 24 hr, internalized pffs were detected in only 34.4% ±
0.6% of IgG-treated neurons, suggesting the turnover of pffs.
Notably, addition of either Syn211 or Syn303 significantly
reduced the proportion of neurons containing internalized hWTell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authors 2057
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Figure 4. Recognition of a-syn pff Epitopes
by a-syn mAbs Is Required for Reduction
of Pathology
(A) Schematic representation of a-syn protein and
epitopes recognized by Syn211 and Syn303. aa,
amino acid.
(B–D) Syn211 was effective in reducing p-a-syn
pathology when neurons were transduced with
hWT, but not with mWT a-syn pffs, as evidenced
by IF (B) and WB (C and D). n = 4 independent
experiments. Values are mean ± SEM. Student’s
t test. ***p < 0.001. The scale bar represents
100 mm. MW, molecular weight.
(E–G) Primary neurons were transduced with myc-
tagged, C-terminally truncated a-syn pffs (h1-
120myc) following treatment with IgG, Syn211, or
Syn303. Syn303, but not Syn211, was effective in
reducing insoluble pathologic aggregates as
shown by IF (E) and WB (F and G). n = 6 inde-
pendent experiments. Values are mean ± SEM.
One-way ANOVA with Bonferroni’s correction.
***p < 0.001. The scale bar represents 100 mm.
(H–J) Primary neurons were transduced with
N-terminally truncated a-syn pff (h32-140)
following treatment with Syn303. As expected,
Syn303 was ineffective at reducing pathology as
evidenced by IF (H) and WB (I and J). n = 3 inde-
pendent experiments. Values are mean ± SEM.
Student’s t test. n.s., not significant. The scale bar
represents 100 mm.a-syn pffs at all time points examined (Figures 3B and 3C).
Furthermore, the half-life of pffs in cultures treated with either
IgG, Syn211, or Syn303 were comparable (16.3–17.0 hr).
Thus, the presence of a-syn mAbs did not affect the turnover
rate of internalized pffs. Together, these data suggest Syn211
or Syn303 prevented a-syn pff entry into neurons, thus reducing
the amount of seeds available for templated recruitment of
endogenous a-syn into pathological aggregates.
To further confirm that a-syn mAbs remained outside neurons,
Syn211 or Syn303was labeled with anti-mouse IgG and an intra-
cellular marker, tau (K9JA), at 7 days after antibody/pff treat-
ments. We found that a-syn mAbs were almost exclusively
outside neurons as there was no colocalization of either
mAb with K9JA (Figure 3D). Next, we found that almost all of
the exogenously added hWT a-syn pffs (positive for Syn204)2058 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authorsremained outside neurons, as evidence
by the lack of Syn204 and K9JA colocali-
zation (Figure 3E). Moreover, we used
anti-mouse IgG1 as a secondary antibody
to detect Syn211 or Syn303 and anti-
mouse IgG2a as a secondary antibody
to detect Syn204 and observed complete
colocalization, indicating that most of the
antibody/a-syn pffs complexes resided
outside neurons (Figure 3F). In addition,
anti-p-a-syn (81A; IgG2a isotype), which
detects intraneuronal p-a-syn aggre-
gates, did not colocalize with either
Syn211 or Syn303, suggesting that theexogenously added a-syn antibodies remained bound to hWT
a-syn pffs outside neurons (Figure 3G).
To further demonstrate blockade of a-syn pff entry as a mech-
anism of action of a-syn mAbs, we took advantage that Syn211
and Syn303 recognize defined epitopes in topographically
distinct domains of a-syn (Figure 4A). Based on its selective
recognition of amino acids 121–125 of human a-syn (Giasson
et al., 2000a), we predicted that Syn211 would be ineffective in
reducing a-syn pathology when neurons were treated with pffs
made from recombinant mouse a-syn (mWT) or from C-termi-
nally Myc-tagged human a-syn that was truncated at amino
acid 120 (h1-120myc). Indeed, Syn211 was unable to reduce
insoluble p-a-syn accumulations in mWT- (Figures 4B–4D) and
h1-120myc a-syn pff-treated neurons as monitored by immuno-
fluorescence (IF) and immunoblotting (Figures 4E–4G).
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Figure 5. a-syn mAbs Prevented Transmission of Pathologic a-syn Aggregates
(A) Schematic of microfluidic neuron device with three chambers to separate neurons seeded in each chamber.
(B) Propagation of pathologic p-a-syn from C1 to C2 to C3 at 7 days and 14 days postaddition of hWT a-syn pffs into non-Tg neurons. Arrowheads indicate
p-a-syn pathology formed within grooves. The scale bar represents 100 mm.
(C–E) To increase amount of transmitted pathologic a-syn aggregates in C3, neurons from Tg mice overexpressing hWT a-syn (M7 line) were used. Because
passive diffusion of mAbs from C2 to C1 occurs and can potentially bind to hWT a-syn pffs in C1 to prevent pff uptake that could account for the observed
reduction in transmitted pathology from C1 to C2 to C3, C- and N-terminally truncated a-syn pffs were used. Specifically, h1-120myc pffs were added to C1,
whereas Syn211 was added to C2 (C) and h32-140 pffs were added to C1, whereas C2 received Syn303 treatment (D). Both Syn211 and Syn303 were ineffective
in preventing C- and N-terminally truncated pff-induced pathology, respectively, in C1 when compared to systems without antibody treatment (no Ab). Syn211
partially blocked templated transmission of pathologic aggregates in C2 (C), whereas Syn303 prevented templated propagation of pathologic a-syn from C1 to
C2 to C3 (D).
(E) Quantification of area occupied bymAb 81A for p-a-syn signal in C1, C2, and C3 of paired chamber devices that either received no antibody treatment (no Ab),
Syn211, or Syn303. n = 3 independent experiments. Values are mean ± SEM. Student’s t test. *p < 0.05, **p < 0.01.On the other hand, Syn303 recognizes a conformational
epitope spanning across amino acids 1–5 in both human and
mouse a-syn (Duda et al., 2002; Giasson et al., 2002; Figure 4A).
Due to its selectivity for the a-syn N terminus, we predicted that
Syn303 would reduce the extent of insoluble aggregates when
neurons were treated with pffs made from h1-120myc a-syn,
but not those made from N-terminally truncated human a-syn
(h32-140). Indeed, Syn303 was efficacious in reducing patho-
logic aggregates when neurons were exposed to h1-120myc
(Figures 4E–4G), but not h32-140 a-syn pffs (Figures 4H–4J). As
an additional control, a Myc antibody (9E10) was able to reduce
pathology when h1-120myc a-syn pffs were used, confirming
blockade of exogenous pff uptake into neurons (Figure S2).
Taken together, these data support our conclusion that a-syn
mAbs reduced pathology by directly interacting with the a-synCpffs added to the culture dish, rather than endogenously ex-
pressed a-syn, and that blockade of pff entry into neurons is
likely the main mechanism underlying the observed reduction
in pathology.
a-synmAbsPrevented Transmission of Pathologic a-syn
Aggregates
To study the effects of mAb treatment on propagation of a-syn
pathology, we used microfluidic culture devices (Taylor et al.,
2005), which comprised of three somal compartments con-
nected in tandem by a series of microgrooves separating three
distinct neuronal populations (Figure 5A).
We first plated non-Tg neurons in all three chambers (C)
and initiated a-syn pathology by adding hWT a-syn pffs to neu-
rons in C1 at day in vitro (DIV) 7. Significantly, we observedell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authors 2059
propagation of pathologic p-a-syn aggregates to cell bodies and
neurites of neurons grown in C2 (at 7 days after pff addition) fol-
lowed by those in C3 (at 14 days; Figure 5B). Importantly, when
h1-120myc pffs were added to C1, we were unable to detect
Myc immunoreactivity in either C2 or C3, indicating that the
hydrostatic gradient effectively prevented passage of these
pffs from C1 (Figure S3A). Thus, our data demonstrate that path-
ologic a-syn induced by pffs in C1 can propagate along axons
and/or dendrites contained within the microgrooves to C2 and
C3. Given that neuronal processes represent the only cellular
contact between individual chambers, the delayed presence of
a-syn pathology in C3 supports cell-to-cell transfer of seeding
material from C1 and/or C2.
To determine whether a-syn mAbs can prevent cell-to-cell
transmission of pathologic a-syn aggregates in this chamber
system, we added Syn211 or Syn303 to C2 30 min prior to add-
ing pffs to C1, where the transfer of pathologic a-syn from
affected neurons to naive neurons would be expected to occur.
Compared with no a-syn mAb treatment, we observed a highly
significant reduction of a-syn pathology in C1 and C2 at 7 and
14 days following treatment with Syn211 and Syn303 (Figures
S3B–S3D). Passive diffusion of mAbs from C2 to C1 could in
part account for this reduction in a-syn aggregates due to the hy-
drostatic gradient used to confine pffs to C1 (Figure 5A) and
hence preventing pff uptake. Moreover, because only a limited
number of the axons from each chamber can pass through the
microgrooves into the next, we were unable to accurately quan-
tify the amount of a-syn pathology in C3 using primary neurons
from non-Tg mice.
To overcome these two limitations, we used primary neurons
generated from homozygous Tg mice overexpressing hWT
a-syn (M7 line; Giasson et al., 2002) to increase the amount of
a-syn pathology and enhance our ability to detect pathological
transmission to neurons in C3. Moreover, to unequivocally iden-
tify cell-to-cell transmitted species, we used pffs assembled
from a-syn lacking the complementary extreme N- or C-terminal
regions recognized by the mAbs. If cell-to-cell transfer of a-syn
pathology indeed occurs in C2 andC3, a-synmAbs should block
this process because the transmissible a-syn species is likely
comprised of full-length a-syn (i.e., endogenous human or
mouse a-syn in the M7 neurons) rather than the truncated
a-syn in pffs. Indeed, when h1-120myc a-syn pffs was added
to C1, Syn211 added to C2 was ineffective in blocking
h-120myc pff-induced pathology in C1 but partially effective in
blocking a-syn pathology in C2, supporting the interpretation
that some of the transmissible species in C2 are human a-syn
(Figures 5C and 5E). When h32-140 a-syn pffs were added to
C1 and Syn303 to C2, Syn303 was ineffective in blocking
a-syn pathology elicited by h32-140 pffs in C1. However,
Syn303 reduced propagation of a-syn pathology in C2 and C3
(Figures 5D and 5E). Because the numbers of DAPI nuclei were
similar in chamber pairs with and without mAb treatment (data
not shown), the reduction in p-a-syn by a-syn mAbs indeed
reflects the blockade of cell-to-cell transmission of a-syn pathol-
ogy. Furthermore, because Syn303 is a species-independent
mAb specific for a misfolded a-syn conformer and does not im-
munostain endogenous and synaptically localized a-syn, the
transmissible species are likely misfolded a-syn conformers2060 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authorsthat are subsequently released and internalized by nearby neu-
rites and cell bodies to template the recruitment of endogenous
a-syn in neurons in C2 and C3. Thus, our results are consistent
with Syn303 reducing pathologic a-syn propagation in C2 and
C3, whereas Syn211 was only able to ameliorate pathology in
C2 (Figure 5E).
Taken together, these data demonstrate that a-syn mAbs
could prevent cell-to-cell transmission of pathologic a-syn
aggregates.
Syn303 Reduced Pathological a-syn Spread In Vivo
Because Syn303 can reduce pathologic a-syn aggregates in pri-
mary neurons and recognizes misfolded a-syn in LBs/LNs in PD
brains and various PD mouse models (Giasson et al., 2000b;
Irwin et al., 2012; Lim et al., 2011; Luk et al., 2012b), we asked
whether Syn303 could reduce a-syn pathology in vivo. We
used a previously established mouse model of sporadic PD
where we showed that a single intrastriatal injection of mWT
a-syn pffs into young WT mice resulted in progressive accumu-
lation of misfolded and hyperphosphorylated a-syn aggregates
at neuroanatomically connected areas including the SNpc and
amygdala (Luk et al., 2012a). To this end, WT mice were inocu-
lated with mWT a-syn pffs and immediately treated with
Syn303 or control IgG (30 mg/kg, intraperitoneally [i.p.]) followed
byweekly treatment for 30 days (Figure 6A). Micewere sacrificed
posttreatment, and brains were processed for immunohisto-
chemistry (IHC) to detect a-syn pathology using 81A mAb for
p-a-syn and Syn506 mAb for misfolded a-syn in LB/LN-like
aggregates (Luk et al., 2012a).
In pff-inoculated, control-IgG-treated mice, pathologic a-syn
aggregates were detected in multiple brain regions including
frontal cortex, SNpc, and the amygdala, primarily ipsilateral
to the injection site (Figure 6B). Importantly, Syn303 treatment
reduced a-syn pathology in these same areas (Figure 6C). Quan-
titative analysis of Syn506-positive aggregates in control-IgG-
and Syn303-treated mice showed significant reduction of
a-syn pathology in the ipsilateral SNpc and contralateral amyg-
dala (Figures 6D and 6F) and a trend toward reduction in the
ipsilateral amygdala (Figure 6E). Thus, the simultaneous admin-
istration of Syn303 mAb and a-syn pffs led to reduction in LB/LN
pathology in our PD mouse model.
To determine whether i.p. administration of Syn303 led to an
appreciable mAb concentration within the brain that demon-
strates effective target engagement (i.e., binding of extracellular
pathologic a-syn), we measured Syn303 levels in the cerebral
spinal fluid (CSF) at 1, 3, and 7 days following a single i.p. injec-
tion (10mg/kg). This dose was chosen based on the use of mAbs
in prior preclinical models, which ranges from 1 to 10 mg/kg
(d’Abramo et al., 2013; Masliah et al., 2011). Within 1 day
following injection, CSF levels of Syn303 reached 0.1% ±
0.002% of the plasma levels (Figure S4), comparable to CSF
levels achieved by other antibodies administered via this route
(Demattos et al., 2012; Wang et al., 2008). Whereas the half-life
of Syn303 mAb in plasma was approximately 60 hr, CSF levels
of Syn303 persisted for the duration of the experiment. These
data further suggest that the observed reduction in pathology
was indeed due to presence of Syn303 mAb in the brain of
mWT pff-injected mice.
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Figure 6. Systemic Treatment of Syn303
Reduced Spread of pff-Induced a-syn Pa-
thology In Vivo
(A) Schematic representation of experimental
design.
(B and C) IHC with mAb 81A for p-a-syn and mAb
Syn506 for misfolded a-syn. Pff inoculation re-
sulted in widespread a-syn pathology at sites with
connection to the striatum such as the ipsilateral
(ipsi) prefrontal cortex, ipsi SNpc, and ipsi and
contralateral (contra) amygdala (B). Syn303 treat-
ment significantly reduced transmission of a-syn
pathology to these regions (C). The scale bar
represents 100 mm.
(D–F) Quantitative analyses of Syn506-positive
aggregates from rostral to caudal SNpc (D), ipsi
(E), and contra amygdala (F) confirmed the quali-
tative observations. n = 8 mice per treatment
group. Values are mean ± SEM. Student’s t test.
*p < 0.05.To test whether Syn303 immunotherapy could retard dis-
ease progression, we initiated treatment with either control
IgG or Syn303 (10 mg/kg) in separate cohorts at 7 days post
pffs injection. At this time point, some a-syn pathology already
is detectable (Figure S5), thus permitting us to determine
whether this mAb could reduce misfolded a-syn propagation.
Following this treatment protocol (Figure S6A), we observed
a significant reduction in numbers of Syn506-positive aggre-
gates in the SNpc and contralateral amygdala of Syn303-
treated mice by 60 days after pff injection (Figures S6B,
S6C, S6F, and S6G) and a trend toward reduction in the ipsi-
lateral amygdala (Figures S6D and S6E). These data demon-
strate that Syn303 treatment can retard the spread of a-syn
pathology in vivo.
Because the accumulation of a-syn aggregates in the SNpc
compromises the survival of dopaminergic neurons over time,
resulting in motor impairments in pff-injected mice, we askedCell Reports 7, 2054–206whether long-term anti-a-syn immuno-
therapy could ameliorate these deficits.
To this end, another cohort of mice was
treated with Syn303 or control IgG
(10 mg/kg) at 7 days post pff inoculation
and then continued weekly for 180 days
(Figure 7A). The animals tolerated long-
term antibody treatment well, as they
gained weight normally and appeared
healthy until the predefined termination
of the experiment. To determine efficacy
of immunotherapy, mice were evaluated
on the wire hang test for grip strength at
30, 90, and 180 days, where we had
observed impairment in this task (Luk
et al., 2012a). At all time points tested,
Syn303 significantly improved grip
strength and motor coordination (Fig-
ure 7B). These mice also exhibited loss
of motor learning and coordination at 90
and 180 days post pff inoculation, asassessed by the rotarod task. However, rotarod performance
was not significantly improved with Syn303 compared to IgG
treatment at these time points (Figure S7A). IHC analyses
showed a significant reduction in Syn506-positive aggregates
in the SNpc (30% reduction) as well as both ipsilateral (40%
reduction) and contralateral amygdala (40% reduction) of
Syn303- compared to IgG-treated mice (Figures 7C–7H). To
determine whether treatment with Syn303 could prevent loss
of tyrosine hydroxylase (TH)-expressing SNpc neurons at
180 days post pff inoculation, we conducted IHC using TH
antibody in IgG- and Syn303-treatedmice (Figure 7I). Quantifica-
tion of TH-positive neurons showed significant loss in the ipsilat-
eral SNpc compared to contralateral SNpc of IgG-treated mice
(Figures 7I and 7J). Syn303 treatment not only ameliorated TH
cell loss in the ipsilateral SNpc compared to the contralateral
SNpc (Figure 7J) but also rescued TH-positive cells in the ipsilat-
eral SNpc of Syn303- compared to IgG-treated mice (Figure 7J).5, June 26, 2014 ª2014 The Authors 2061
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Figure 7. Syn303 Reduced pff-Induced Motor Dysfunction and Dopaminergic Cell Loss
(A) Schematic representation of experimental design.
(B) Wire hang performance ofWTmice at 30 days, 90 days, and 180 days post pff inoculation with control IgG or Syn303 treatment. Longer latency to fall equated
to better performance. n = 15 mice per treatment group. Student’s t test. *p < 0.05.
(C–H) Syn303 treatment significantly reduced pathologic spread of Syn506-positive aggregates in the SNpc (C and D) and ipsi (E and F) and contra amygdala
(G and H). n = 12 mice per treatment group. Values are mean ± SEM. Student’s t test. *p < 0.05, **p < 0.01. The scale bars represent 100 mm.
(I) TH cells loss was evident in the ipsi, but not the contra, SNpc of control IgG-treated mice. Syn303 treatment ameliorated TH cell loss. The scale bar represents
100 mm.
(J) Quantification of TH-positive cells showed 35% TH cell loss in the ipsi SNpc compared to the contra SNpc in control IgG-treated mice at 180 days post pff
inoculation. Syn303 treatment ameliorated this TH cell loss. n = 12 mice per treatment group. Values are mean ± SEM. One-way ANOVA with Bonferroni’s
correction. *p < 0.05, **p < 0.01.We also assessed changes in astrocyte and microglia activa-
tion via IHC with GFAP and Iba1 antibodies, respectively, but did
not observe marked differences in the extent of astrogliosis and
microgliosis in IgG- versus Syn303-treated mice (Figures S7B–
S7E). We surmise this reflects the modest SNpc neurodegener-
ation at this time.
Taken together, a-syn immunotherapy using Syn303 reduced
pathologic spread of a-syn aggregates in vivo, ameliorated
motor dysfunction mediated by LB pathology, and rescued TH
cell loss.
DISCUSSION
Our study demonstrates efficacy of anti-a-syn immunotherapy
in reducing LB/LN-like pathology formation and spread in
physiologically relevant in vitro and in vivo models of PD-like2062 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authorssynucleinopathy. Indeed, in primary neurons treated with a-syn
pffs, a-syn mAbs were capable of impeding recruitment of
endogenous a-syn into pathologic aggregates as well as preser-
ving normal synaptic localization of a-syn, mitigating synaptic
and neuron loss caused by pathologic a-syn. Likewise, in WT
mice inoculated with a-syn pffs into the striatum, anti-a-syn
immunotherapy reduced the spread of pathologic a-syn,
rescuing dopaminergic SNpc neuron loss and the associated
motor deficits induced by transmission of a-syn pathology.
Thus, a-syn mAbs interrupt a reiterative chain of detrimental
changes following the templated conversion of normal endoge-
nous mouse a-syn by a-syn pffs in neurons.
Several lines of evidence support the self-templating, amplifi-
cation, and cell-to-cell transmission of misfolded protein seeds
as the underlying mechanism for the progression andmanifesta-
tion of several major NDs (Costanzo and Zurzolo, 2013; Guo and
Lee, 2014;Walker and Jucker, 2013). Here, we extend these pre-
vious observations by demonstrating that LB/LN-like pathology
induced by a-syn pffs propagates both intracellularly within neu-
rons and intercellularly between neurons through the use of a
triple microfluidic chamber system that allows for physical isola-
tion of distinct neuronal populations. Using this system, we
demonstrate that a-syn pathology induced by a-syn pffs within
one chamber is progressively amplified and propagated to
downstream neuron populations. Moreover, the efficacy of
a-syn mAbs in reducing pathological a-syn and spread advo-
cates targeting extracellular protein seeds as viable therapeutic
options for the treatment of NDs, and our triple chamber
neuronal system will be useful for future testing of compounds
that may retard or halt cell-to-cell transmission of disease pro-
teins like a-syn.
Our study suggests two possible mechanisms by which a-syn
mAbs reduced pathologic a-syn. First, a-syn mAbs could block
pff uptake into neurons, thereby limiting the amount of seeds
available for recruitment of endogenous a-syn into pathologic
aggregates. Indeed, the majority of added pffs remained outside
neurons, where they colocalized with the a-syn mAbs, but not
with intracellular neuronal markers. Furthermore, dramatically
lower number of neurons with internalized a-syn pffs was
observed in the presence of a-syn mAbs, and the turnover rate
of intracellular pffswasnot affectedbymAb treatment.Moreover,
in h1-120myc a-syn pff-treated culture, a Myc antibody dramat-
ically reduced a-syn pathology, thereby providing unequivocal
evidence that eliminating the exogenous source is driving pathol-
ogy reduction. This concept of inhibiting fibril entry as a mecha-
nism of immunotherapy was also demonstrated recently for tau
antibodies in tau-overexpressing nonneuronal cell models
(Kfoury et al., 2012; Yanamandra et al., 2013) as well as in a Tg
mouse model of tauopathy (Yanamandra et al., 2013).
A second potential mechanism for a-syn mAbs is the preven-
tion of cell-to-cell transmission of pathologic a-syn. In this re-
gard, the utilization of the triple microfluidic system allowed us
to demonstrate that a-syn mAbs impeded progressive propaga-
tion and spread of pathologic a-syn from neurons grown in one
chamber to another. Presumably, this occurred within neurons
that had internalized a-syn pffs, but more studies are needed
to confirm this issue. Importantly, the two mechanisms we pro-
pose to account for how a-syn mAbs reduce pathologic a-syn
are not mutually exclusive, and it is plausible that they could
operate simultaneously.
Consistent with our in vitro findings, the a-syn mAb Syn303
was effective in arresting initiation and halting progression of
a-syn pathology in vivo. By treating WTmice with Syn303 imme-
diately after intrastriatal inoculation of mWT a-syn pffs, which
presumably inhibits pff uptake, we demonstrated a reduction
in pathologic a-syn aggregates in brain regions with direct
connection to the striatum, including prefrontal cortex, SNpc,
and amygdala. By treating themice at 7 days post a-syn pff inoc-
ulation, a time at which some a-syn pathology was already
observed, Syn303 was able to inhibit transmission of a-syn
pathology and retard disease progression, as evidenced by
reduced pathologic spread of a-syn throughout multiple CNS re-
gions. Currently, it is unclear whether a-syn mAbs mediate the
clearance of Lewy pathology in our sporadic PD model of WTCmice. Based on previous reports of active and passive a-syn
immunization in Tg mice overexpressing human a-syn, a-syn
antibodies might facilitate degradation of a-syn aggregates by
promoting lysosomal and/or autophagic clearance (Masliah
et al., 2005, 2011) whereas another passive a-syn immuno-
therapy study supported the role of microglia in antibody-medi-
ated clearance of a-syn aggregates (Bae et al., 2012). Future
in vivo studies should aim at determining the metabolic fate of
the antibody/a-syn complexes as well as sorting out the exact
mechanism(s) of immune therapy in vivo.
Despite a lack of understanding of disease mechanisms un-
derlying transmissible a-syn release and uptake into neurons in
synucleinopathies brains and factors responsible for initiating
a-syn misfolding and fibrillization, our study supports that the
transmissible species likely comprised of endogenous mis-
folded a-syn for the following reasons. First, using triple cham-
ber system cultured with M7 neurons that overexpress human
a-syn, we showed that both Syn211, a C-terminal, human-spe-
cific a-syn mAb, and Syn303, a species-independent, N-termi-
nal mAb against misfolded a-syn, retarded the spread of
pathologic a-syn from neurons grown in one chamber to the
other two downstream chambers, even when C- and N-termi-
nally truncated a-syn pffs were added to seed recruitment of
endogenous a-syn. This suggests that the transmissible spe-
cies are most likely endogenous a-syn protein (human or
mouse a-syn), because Syn211 and Syn303 continued to
inhibit propagation, even though neither of the mAbs recognize
exogenously added C- and N-terminally truncated a-syn pffs,
respectively. Second, we postulated that the transmitted spe-
cies are likely misfolded a-syn because mAb Syn303 only rec-
ognizes misfolded, but not normal, a-syn, and this mAb is
effective in preventing a-syn pathology propagation from C1
to C2 and then to C3. We also found that 81A, a mAb against
p-a-syn, was less effective at reducing pathologic a-syn forma-
tion and spread in both in vitro and in vivo systems (data not
shown). Together, these data suggest that the transmissible
a-syn species originate from templated recruitment of endoge-
nously expressed a-syn protein that is misfolded, but not
necessarily phosphorylated.
Previous reports of anti-a-syn immunotherapy showed effi-
cacy of C-terminal a-synmAbs recognizing linear a-syn epitopes
in clearing intracellular aggregates (Bae et al., 2012; Masliah
et al., 2011). Similarly, Syn211, which binds to amino acids
121–125 of human a-syn, was very potent in preventing fibrils
entry and reducing a-syn pathology in our primary neuron sys-
tems. Higher affinity of Syn211 for a-syn compared to Syn303
(data not shown) likely accounted for the observed increase in
efficacy of Syn211 compared with Syn303 in our in vitro experi-
ments. However, because our sporadic PD-like model uses non-
Tg mice, whether our human-specific Syn211 is effective in vivo
remains to be determined. Nonetheless, the efficacy of Syn303,
an N-terminal mAb to misfolded a-syn, demonstrates that
both conformation and affinity are important determinants for
successful a-syn immunotherapy.
Timing of intervention by a-syn immunotherapy is another
important factor to be considered. In primary neurons, a-syn
mAbs were effective when added 30 min prior to and up to
1 day post pff addition (data not shown). In our in vivo model,ell Reports 7, 2054–2065, June 26, 2014 ª2014 The Authors 2063
a-syn immunotherapy reduced pathological a-syn spread if
given immediately or up to 7 days post pff inoculation in mice.
Thus, immunotherapy against disease proteins may only be effi-
cacious in treatment of NDs early during the course of disease.
Finally, our recent studies suggest that there may be a-syn
‘‘strains,’’ which, when transmitted from cell to cell, can give
rise to morphologically distinct Lewy pathology that could
account for different types of synucleinpathies with diverse clin-
ical phenotypes (Guo et al., 2013). We speculate that the trans-
missible species of pathological a-syn may reflect adaptation
of the specific conformations templated by the initial seeds
such that it may be possible to design therapeutic antibodies
and/or compounds that are specific to these conformers.
Perhaps strain-independent mAbs that bind a wide variety of
misfolded forms of a-syn will be required to robustly block prop-
agation in vivo, as strains may evolve during the disease pro-
cess. Future studies will be required to address this question.
In conclusion, the observation that antibodies targeting aber-
rant species of a-synmarkedly reduce uptake and spread of PD-
like LB/LN-like pathology provides evidence to support the
hypothesis that transmission of pathological a-syn is a central
event in the progression of PD and related synucleinopathies.
Thus, targeting transmissible misfolded species of a-syn is a
potential strategy to halt progression of PD and related
synucleinopathies.
EXPERIMENTAL PROCEDURES
Animals
WT mice (CD1 or C57BL6/C3H background) were purchased from Charles
River Laboratories. All studies were performed according to the National Insti-
tutes of Health (NIH) Guide for the Care and Use of Experimental Animals and
approved by the University of Pennsylvania Institutional Animal Care and Use
Committee.
Primary Neuronal Cultures, Fibril Transduction, and Antibody
Treatment in Primary Neurons
Primary hippocampal cultures were prepared from E16 to E18 CD1 or M7
mouse brains and maintained as described (Volpicelli-Daley et al., 2011). Fibril
transduction was performed at 7–10 DIV as described (Volpicelli-Daley et al.,
2011). For antibody treatment, neurons were treated with a-syn mAbs
30 min prior to a-syn pff addition. Unless otherwise noted, 6 mg/ml and
15 mg/ml of antibody were used in most IHC and biochemical experiments,
respectively. Each experiment was performed in duplicates and repeated
3–10 times. Transduced neurons were harvested for indirect IF and sequential
extraction (see Supplemental Information for details).
Microfluidic Chambers
Triple compartments microfluidic devices were obtained from Xona Microflui-
dic (TCND500). Glass coverslips were prepared and coated as described
before being affixed to microfluidic devices (Volpicelli-Daley et al., 2011).
Approximately 120,000 neurons were plated per chamber. At DIV7, 3 mg of
a-syn mAbs were added to C2 at 30 min before addition of 0.5 mg a-syn pff
to C1. To control for direction of flow, a 75 ml difference in media volume
wasmaintained between C1 and C2 andC2 andC3 according to themanufac-
turers’ instructions. Neurons were fixed 7 or 14 days after mAb/pff treatments
using 4% paraformaldehyde and 4% sucrose in PBS. Devices were then
removed from cover glass for IF (see Supplemental Information for details).
LDH Toxicity Assay
LDH release assay (Promega; CytoTox 96 NonRadioactive Cytotoxicity Assay)
was performed according to manufacturer’s instruction (see Supplemental
Information for details).2064 Cell Reports 7, 2054–2065, June 26, 2014 ª2014 The AuthorsStereotaxic Injections of a-syn pff, Antibody Treatment, and IHC
All surgical procedures were performed as previously described (Luk et al.,
2012a). An equal proportion of male and female mice were used for each
experiment. Either immediately or at 7 days post pff injection, mice were
treated with Syn 303 or control IgG1 antibody at 30 mg/kg or 10 mg/kg via
i.p. injections, respectively. They received weekly i.p. injections of antibodies
until sacrifice at predetermined periods: 30 days, 60 days, and 180 days.
IHC was done as previously described (Luk et al., 2012a, 2012b; see Supple-
mental Information for details).
Direct ELISA
A direct a-syn ELISA using mouse a-syn pff as coating material was used to
determine the levels of a-syn antibody in plasma and CSF (see Supplemental
Information for details).
Behavioral Assessments
Behavioral tests were performed as described (Luk et al., 2012a), except that
the wire hang test was stopped if mice remained suspended for over 10 min
(see Supplemental Information for details).
Statistics
For pairwise comparisons, Student’s t tests were used. For comparisons of
more than two treatment groups, one-way ANOVA with Bonferroni or
Dunnett’s post hoc tests were used. Statistical significance was set to p <
0.05. Values are shown as mean ± SEM unless otherwise indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.05.033.
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